Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study; First clinical study of a rationally-defined bacterial consortium (VE416) for treating food allergy, will initially be studied in patients with history o

Media coverage

• Title	Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study; First clinical study of a rationally-defined bacterial consortium (VE416) for treating food allergy, will initially be studied in patients with history o
  Media name/outlet	Business Wire
  Country/Territory	United States
  Date	1/07/19
  Persons	Jeremiah Faith